Toward a Radically Simple Multi-Modal Nasal Spray for Preventing Respiratory Infections

Bibliographische Detailangaben
Veröffentlicht in:	Advanced materials (Deerfield Beach, Fla.). - 1998. - (2024) vom: 24. Sept., Seite e2406348
1. Verfasser:	Joseph, John (VerfasserIn)
Weitere Verfasser:	Baby, Helna Mary, Quintero, Joselyn Rojas, Kenney, Devin, Mebratu, Yohannes A, Bhatia, Eshant, Shah, Purna, Swain, Kabir, Lee, Dongtak, Kaur, Shahdeep, Li, Xiang-Ling, Mwangi, John, Snapper, Olivia, Nair, Remya, Agus, Eli, Ranganathan, Sruthi, Kage, Julian, Gao, Jingjing, Luo, James N, Yu, Anthony, Park, Dongsung, Douam, Florian, Tesfaigzi, Yohannes, Karp, Jeffrey M, Joshi, Nitin
Format:	Online-Aufsatz
Sprache:	English
Veröffentlicht:	2024
Zugriff auf das übergeordnete Werk:	Advanced materials (Deerfield Beach, Fla.)
Schlagworte:	Journal Article antibacterial antiviral broad spectrum protection nasal prophylaxis nasal spray pathogen capture respiratory infections virus neutralization

Beschreibung
Zusammenfassung:	© 2024 Wiley‐VCH GmbH. Nasal sprays for pre-exposure prophylaxis against respiratory infections show limited protection (20-70%), largely due to their single mechanism of action-either neutralizing pathogens or blocking their entry at the nasal lining, and a failure to maximize the capture of respiratory droplets, allowing them to potentially rebound and reach deeper airways. This report introduces the Pathogen Capture and Neutralizing Spray (PCANS), which utilizes a multi-modal approach to enhance efficacy. PCANS coats the nasal cavity, capturing large respiratory droplets from the air, and serving as a physical barrier against a broad spectrum of viruses and bacteria, while rapidly neutralizing them with over 99.99% effectiveness. The formulation consists of excipients identified from the FDA's Inactive Ingredient Database and Generally Recognized as Safe list to maximize efficacy for each step in the multi-modal approach. PCANS demonstrates nasal retention for up to 8 hours in mice. In a severe Influenza A mouse model, a single pre-exposure dose of PCANS leads to a >99.99% reduction in lung viral titer and ensures 100% survival, compared to 0% in the control group. PCANS suppresses pathological manifestations and offers protection for at least 4 hours. This data suggest PCANS as a promising daily-use prophylactic against respiratory infections
Beschreibung:	Date Revised 07.11.2024 published: Print-Electronic Citation Status Publisher
ISSN:	1521-4095
DOI:	10.1002/adma.202406348